Vivani Medical, Inc. (VANI) has received regulatory approval to begin human clinical trials for its innovative miniature, subdermal GLP-1 (exenatide) implant in Australia. This first-in-human trial, dubbed LIBERATE-1, will assess the safety, tolerability, and pharmacokinetic profile of the implant in obese and overweight individuals. The trial is expected to commence in the fourth quarter of 2024 and is anticipated to yield data in 2025.
Vivani Medical, Inc. (VANI) announced promising preclinical results for its exenatide implant, demonstrating a significant reduction in liver fat in obese mice. This implant, which delivers the drug exenatide (sold as Byetta and Bydureon for diabetes), could potentially offer a highly differentiated treatment option for obesity and related metabolic disorders. Vivani is preparing to launch its first human clinical trial, LIBERATE-1, later this year.
